Product nameAnti-Factor VIII antibody
See all Factor VIII primary antibodies
DescriptionSheep polyclonal to Factor VIII
SpecificityNo reactivity was observed with von Willebrand Factor.
Tested applicationsSuitable for: ELISA, IHC-P, IHC-Fr, Immunodiffusionmore details
Species reactivityReacts with: Human
Human Factor VIII purified from Factor VIII concentrate.
- Human skeletal muscle and capillaries
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
Constituents: 0.24% HEPES, 50% Glycerol, 0.88% Sodium chloride
Concentration information loading...
PurityAmmonium Sulphate Precipitation
Our Abpromise guarantee covers the use of ab139391 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent dilution.|
|IHC-P||Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|IHC-Fr||Use at an assay dependent concentration.|
|Immunodiffusion||Use at an assay dependent concentration.|
FunctionFactor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.
Involvement in diseaseDefects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Note=Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non-functional; i.e., the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
Sequence similaritiesBelongs to the multicopper oxidase family.
Contains 3 F5/8 type A domains.
Contains 2 F5/8 type C domains.
Contains 6 plastocyanin-like domains.
DomainDomain F5/8 type C 2 is responsible for phospholipid-binding and essential for factor VIII activity.
modificationsSulfation on Tyr-1699 is essential for binding vWF.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- AHF antibody
- Antihemophilic factor antibody
- Coagulation factor VIII antibody
This product has been referenced in:
- Yang J et al. Case report of ocular Kaposi's sarcoma. BMC Ophthalmol 17:143 (2017). Read more (PubMed: 28806949) »
- Wang Q et al. Method for in vitro differentiation of bone marrow mesenchymal stem cells into endothelial progenitor cells and vascular endothelial cells. Mol Med Rep 14:5551-5555 (2016). ICC/IF ; Dog, Human . Read more (PubMed: 27878275) »